Pfizer Beats Sales Estimates
Digest more
By Mariam Sunny and Christy Santhosh May 5 (Reuters) - Pfizer said on Tuesday that it expects to return to stronger growth after 2028, driven by obesity drugs in development, a patent extension for its heart drug Vyndamax and a favorable European court ruling on its COVID-19 vaccine.
Higher sales of cancer treatments helped fuel better-than-expected first-quarter sales and profit for the drugmaker.
The pharmaceutical company has been investing in its future growth, but whether its efforts will pay off is a big question mark.
NEW YORK, N.Y. — Pfizer announced Wednesday that data shows a third dose of its COVID-19 vaccine can “strongly” boost protection against the highly transmissible delta variant. The pharmaceutical and biotechnology company made the announcement in a ...
Pfizer Inc. (NYSE:PFE) is one of the best inexpensive stocks to buy now. On January 20, Novavax announced a non-exclusive licensing agreement with Pfizer, granting the pharmaceutical giant access to its Matrix-M adjuvant tech. This technology is designed ...
Pfizer Inc. and Novo Nordisk A/S boosted their bids for obesity startup Metsera Inc. Novo’s updated offer values Metsera at a total of $10 billion, compared to the offer from Pfizer, which values the company at about $8.1 billion. Madison Muller reports ...